Clinical Trials · NCT07446998
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Veru Inc.
- Enrollment
- 200
- Start date
- Mar 2026
- Locations
- 14 sites, United States
- Primary endpoint
- To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone.